Literature DB >> 28277671

Enzyme-Cleavable Polymeric Micelles for the Intracellular Delivery of Proapoptotic Peptides.

Hanna B Kern1, Selvi Srinivasan1, Anthony J Convertine1, David Hockenbery2, Oliver W Press2, Patrick S Stayton1.   

Abstract

Peptides derived from the third Bcl-2 homology domain (BH3) renormalize apoptotic signaling by antagonizing prosurvival Bcl-2 family members. These potential peptide drugs exhibit therapeutic activities but are limited by barriers including short circulation half-lives and poor penetration into cells. A diblock polymeric micelle carrier for the BIM BH3 peptide was recently described that demonstrated antitumor activity in a B-cell lymphoma xenograft model [Berguig et al., Mol. Ther. 2015, 23, 907-917]. However, the disulfide linkage used to conjugate the BIM peptide was shown to have nonoptimal blood stability. Here we describe a peptide macromonomer composed of BIM capped with a four amino acid cathepsin B substrate (FKFL) that possesses high blood stability and is cleaved to release the drug inside of target cells. Employing RAFT polymerization, the peptide macromonomer was directly integrated into a multifunctional diblock copolymer tailored for peptide delivery. The first polymer block was made as a macro-chain transfer agent (CTA) and composed of a pH-responsive endosomolytic formulation of N,N-diethylaminoethyl methacrylate (DEAEMA) and butyl methacrylate (BMA). The second polymer block was a copolymer of the peptide and polyethylene glycol methacrylate (PEGMA). PEGMA monomers of two sizes were investigated (300 Da and 950 Da). Protein gel analysis, high performance liquid chromatography, and coupled mass spectrometry (MS) showed that incubation with cathepsin B specifically cleaved the FKFL linker and released active BIM peptide with PEGMA300 but not with PEGMA950. MALDI-TOF MS showed that incubation of the peptide monomers alone in human serum resulted in partial cleavage at the FKFL linker after 12 h. However, formulation of the peptides into polymers protected against serum-mediated peptide degradation. Dynamic light scattering (DLS) demonstrated pH-dependent micelle disassembly (25 nm polymer micelles at pH 7.4 versus 6 nm unimers at pH 6.6), and a red blood cell lysis assay showed a corresponding increase in membrane destabilizing activity (<1% lysis at pH 7.4 versus 95% lysis at pH 6.6). The full carrier-drug system successfully induced apoptosis in SKOV3 ovarian cancer cells in a dose-dependent manner, in comparison to a control polymer containing a scrambled BIM peptide sequence. Mechanistic analysis verified target-dependent activation of caspase 3/7 activity (8.1-fold increase), and positive annexin V staining (72% increase). The increased blood stability of this enzyme-cleavable peptide polymer design, together with the direct polymerization approach that eliminated postsynthetic conjugation steps, suggests that this new carrier design could provide important benefits for intracellular peptide drug delivery.

Entities:  

Keywords:  RAFT polymerization; apoptosis; cathepsin B; intracellular drug delivery; pH-responsive polymer; therapeutic peptide

Mesh:

Substances:

Year:  2017        PMID: 28277671      PMCID: PMC5823688          DOI: 10.1021/acs.molpharmaceut.6b01178

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  58 in total

1.  Diblock copolymers with tunable pH transitions for gene delivery.

Authors:  Matthew J Manganiello; Connie Cheng; Anthony J Convertine; James D Bryers; Patrick S Stayton
Journal:  Biomaterials       Date:  2011-12-12       Impact factor: 12.479

2.  Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins.

Authors:  Shinichi Kitada; Marilisa Leone; Sina Sareth; Dayong Zhai; John C Reed; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2003-09-25       Impact factor: 7.446

3.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Authors:  Mai Nguyen; Richard C Marcellus; Anne Roulston; Mark Watson; Lucile Serfass; S R Murthy Madiraju; Daniel Goulet; Jean Viallet; Laurent Bélec; Xavier Billot; Stephane Acoca; Enrico Purisima; Adrian Wiegmans; Leonie Cluse; Ricky W Johnstone; Pierre Beauparlant; Gordon C Shore
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

Review 4.  BCL-2 family antagonists for cancer therapy.

Authors:  Guillaume Lessene; Peter E Czabotar; Peter M Colman
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer.

Authors:  Craig L Duvall; Anthony J Convertine; Danielle S W Benoit; Allan S Hoffman; Patrick S Stayton
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

7.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

8.  pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.

Authors:  John T Wilson; Salka Keller; Matthew J Manganiello; Connie Cheng; Chen-Chang Lee; Chinonso Opara; Anthony Convertine; Patrick S Stayton
Journal:  ACS Nano       Date:  2013-04-30       Impact factor: 15.881

9.  Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

Authors:  Barbara Becattini; Shinichi Kitada; Marilisa Leone; Edward Monosov; Sharon Chandler; Dayong Zhai; Thomas J Kipps; John C Reed; Maurizio Pellecchia
Journal:  Chem Biol       Date:  2004-03

10.  Contribution of linker stability to the activities of anticancer immunoconjugates.

Authors:  Stephen C Alley; Dennis R Benjamin; Scott C Jeffrey; Nicole M Okeley; Damon L Meyer; Russell J Sanderson; Peter D Senter
Journal:  Bioconjug Chem       Date:  2008-03-04       Impact factor: 4.774

View more
  7 in total

1.  Extremely long tumor retention, multi-responsive boronate crosslinked micelles with superior therapeutic efficacy for ovarian cancer.

Authors:  Wenwu Xiao; Nell Suby; Kai Xiao; Tzu-Yin Lin; Nasir Al Awwad; Kit S Lam; Yuanpei Li
Journal:  J Control Release       Date:  2017-08-25       Impact factor: 9.776

2.  Theranostic Nanosystems for Targeted Cancer Therapy.

Authors:  Homan Kang; Shuang Hu; Mi Hyeon Cho; Suk Ho Hong; Yongdoo Choi; Hak Soo Choi
Journal:  Nano Today       Date:  2018-11-16       Impact factor: 20.722

3.  A facile strategy for fine-tuning the stability and drug release of stimuli-responsive cross-linked micellar nanoparticles towards precision drug delivery.

Authors:  Kai Xiao; Tzu-Yin Lin; Kit S Lam; Yuanpei Li
Journal:  Nanoscale       Date:  2017-06-14       Impact factor: 7.790

4.  A Novel Anti-CD22 scFv.Bim Fusion Protein Effectively Induces Apoptosis in Malignant B cells and Promotes Cytotoxicity.

Authors:  Zahra Mohammadi; Somayeh Enayati; Najmeh Zarei; Samaneh Saberi; Ladan Mafakher; Mohammad Azizi; Vahid Khalaj
Journal:  Appl Biochem Biotechnol       Date:  2022-07-15       Impact factor: 3.094

Review 5.  Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments.

Authors:  Johan Karlsson; Hannah J Vaughan; Jordan J Green
Journal:  Annu Rev Chem Biomol Eng       Date:  2018-03-26       Impact factor: 11.059

Review 6.  Novel Peptide Therapeutic Approaches for Cancer Treatment.

Authors:  Caroline M Li; Pouya Haratipour; Robert G Lingeman; J Jefferson P Perry; Long Gu; Robert J Hickey; Linda H Malkas
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

7.  A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.

Authors:  Thomas E J Chavas; Fang-Yi Su; Selvi Srinivasan; Debashish Roy; Brian Lee; Lara Lovelace-Macon; Guilhem F Rerolle; Elaine Limqueco; Shawn J Skerrett; Daniel M Ratner; T Eoin West; Patrick S Stayton
Journal:  J Control Release       Date:  2020-11-19       Impact factor: 9.776

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.